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ABSTRACT
Objective: To determine costs and effects of selective
digestive tract decontamination (SDD) and selective
oropharyngeal decontamination (SOD) as compared
with standard care (ie, no SDD/SOD (SC)) from a
healthcare perspective in Dutch Intensive Care Units
(ICUs).
Design: A post hoc analysis of a previously performed
cluster-randomised trial (NEJM 2009;360:20).
Setting: 13 Dutch ICUs.
Participants: Patients with ICU-stay of >48 h that
received SDD (n=2045), SOD (n=1904) or SC
(n=1990).
Interventions: SDD or SOD.
Primary and secondary outcome measures:
Effects were based on hospital survival, expressed as
crude Life Years Gained (cLYG). The incremental cost-
effectiveness ratio (ICER) was calculated, with
corresponding cost acceptability curves. Sensitivity
analyses were performed for discount rates, costs of
SDD, SOD and mechanical ventilation.
Results: Total costs per patient were €41 941 for SC
(95% CI €40 184 to €43 698), €40 433 for SOD (95%
CI €38 838 to €42 029) and €41 183 for SOD (95% CI
€39 408 to €42 958). SOD and SDD resulted in crude
LYG of +0.04 and +0.25, respectively, as compared
with SC, implying that both SDD and SOD are
dominant (ie, cheaper and more beneficial) over SC. In
cost-effectiveness acceptability curves probabilities for
cost-effectiveness, compared with standard care,
ranged from 89% to 93% for SOD and from 63% to
72% for SDD, for acceptable costs for 1 LYG ranging
from €0 to €20 000. Sensitivity analysis for mechanical
ventilation and discount rates did not change
interpretation. Yet, if costs of the topical component of
SDD and SOD would increase 40-fold to €400/day and
€40/day (maximum values based on free market prices
in 2012), the estimated ICER as compared with SC for
SDD would be €21 590 per LYG. SOD would remain
cost-saving.
Conclusions: SDD and SOD were both effective and
cost-saving in Dutch ICUs.
ARTICLE SUMMARY
Article focus
▪ Selective digestive tract decontamination (SDD)
and selective oropharyngeal decontamination
(SOD) are prophylactic antibiotics used as infec-
tion prevention strategy in intensive care units
(ICU).
▪ In a Dutch 13-centre study, SDD and SOD were
associated with relative risk reductions of mortal-
ity at day 28 of 13% and 11%, respectively, as
compared with standard care (SC; ie, no SDD or
SOD) and with lower incidence of ICU-acquired
bacteraemia and ICU-acquired colonisation of the
respiratory tract with multiresistant bacteria.
▪ This paper describes the costs and effects of
SDD and SOD from the healthcare perspective in
Dutch ICUs.
Key messages
▪ Both SDD and SOD were cheaper and more
beneficial as compared with SC and these find-
ings were insensitive to changes in discount
rates and extra costs for ventilation days.
▪ SOD, but not SDD, was still dominant (ie,
cheaper and more beneficial) over SC to current
40-fold higher market-prices of the topical com-
ponents (€40/day for SOD and €400/day for
SDD).
Strengths and limitations of this study
▪ This is the first head-to-head comparison of the
costs and benefits of SDD and SOD and the first
comparison of both interventions versus SC
using data from a multicentre trial including
5939 patients.
▪ Baseline differences were present between the
three study groups.
▪ Only direct medical costs were included in the
analysis and cost data were restricted to health-
care settings.
Oostdijk EAN, de Wit GA, Bakker M, et al. BMJ Open 2013;3:e002529. doi:10.1136/bmjopen-2012-002529 1
Open Access Research
group.bmj.com on November 23, 2014 - Published by http://bmjopen.bmj.com/Downloaded from 
INTRODUCTION
Many patients in Intensive Care Units (ICU) are affected
by nosocomial infections.1 These infections are asso-
ciated with increased mortality and morbidity, and con-
siderable extra expenditure.2 Selective oropharyngeal
decontamination (SOD) and selective decontamination
of the digestive tract (SDD) are prophylactic antibiotic
regimens, that consist of topical antibiotics applied to
the oropharynx and the intestinal tract to prevent colon-
isation of Gram-negative bacteria, Staphylococcus aureus
and yeasts. During SOD topical antibiotics are exclu-
sively applied to the oropharynx throughout the
ICU-stay. During SDD topical antibiotics are not only
applied to the oropharynx but also to the intestinal tract
throughout the ICU-stay, in combination with intraven-
ous administration of cefotaxime during the ﬁrst 4 days
in ICU, to pre-emptively treat infections with commensal
respiratory tract bacteria.3 SDD has been a widely evalu-
ated but highly controversial intervention in ICU.4
Many, but not all, studies reported statistically signiﬁcant
reductions in the incidence of Ventilator-Associated
Pneumonia (VAP), but only few were able to demon-
strate outcome beneﬁts such as reduced mortality and
length of ICU-stay.5 In the absence of indisputably docu-
mented outcome beneﬁts, the fear for selection of anti-
biotic resistance has prevailed and SDD has not been
recommended in most infection prevention guide-
lines.6–9 In a cluster-randomised study in 13 Dutch ICUs,
SDD and SOD were associated with relative risk (RR)
reductions of mortality on day 28 of 13% and 11%,
respectively, as compared with standard care (SC; ie, no
SDD or SOD).3 Although SOD and SDD are currently
widely used in Dutch ICUs, the costs and effects of both
regimens have not yet been determined. We, therefore,
conducted a cost-effectiveness analysis (CEA), compar-
ing SC, SOD and SDD using data from the Dutch multi-
centre trial.
METHODS
Data collection
A post hoc analysis of the cluster randomised crossover
trial comparing SOD and SDD to SC was performed.
The trial was conducted in 13 Dutch ICUs and included
5939 patients (2045 received SDD, 1904 received SOD
and 1990 were treated according to SC). All centres
were assigned to all three regimens during periods of
6 months; however, the order of implementation of SC,
SOD and SDD was randomised per centre.3
SOD and SDD have been described in detail else-
where.3 In short, SOD consists of a paste applied to the
oropharynx, containing polymyxin E, tobramycin and
amphotericin B (all in a 2% concentration, applied
every 6 h). SDD consists, besides the paste used in SOD,
also of a 10 ml suspension of 100 mg polymyxin E,
80 mg tobramycin and 500 mg amphotericin B that is
applied via a nasogastric tube, every 6 h, and of cefotax-
ime (1000 mg, every 6 h) applied intravenously during
the ﬁrst 4 days of ICU-admission. The topical antibiotics
of both regimens are applied until ICU-discharge.
During the trial there were no restrictions to systemic
antibiotic use during SC and SOD. During SDD, the use
of antibiotics with antianaerobic activity was discouraged.
This resulted in a marked increase of cephalosporin use
and lower usage of penicillins, carbapenem and clinda-
mycin.3 Surveillance cultures of endotracheal aspirates,
oropharynx and rectum were obtained upon admission
and twice weekly during SDD. During SOD surveillance,
cultures of endotracheal aspirates and the oropharynx
were obtained upon admission and twice weekly there-
after. During SC no surveillance cultures were obtained.
Clinical cultures were obtained on clinical suspicion of
infection in all three periods.
Approach for economic evaluation
We performed a CEA from a healthcare perspective,
hence, only including direct medical costs.10–12 The
time horizon of the study was the period from
ICU-admission until hospital-discharge. Life Years
Gained (LYG) was used as effectiveness measure. The
outcome of the CEA was the incremental cost effective-
ness ratio (ICER), expressed as cost per LYG. The infor-
mal Dutch threshold for cost-effectiveness is €20 000/
LYG.13 14 Data from all individual patients were used for
analyses. The CEA was performed post hoc, however,
using data that were prospectively collected in Case
Report Forms during the trial. Total direct medical costs
of the three regimens consisted of three main categor-
ies: Length of Stay (LOS), antibiotic use and microbiol-
ogy costs (table 1). LOS was based on the length of
ICU-stay and the number of days on a hospital ward
after ICU-discharge. Costs for days in ICU and other
hospital days were based on the Dutch guidelines for
costing research in health economic studies.11 Days in
ICU were categorised in days with and without mechan-
ical ventilation; days with mechanical ventilation were
considered to be 15% more expensive than ICU-days
without mechanical ventilation.15–17 Antibiotic use con-
sisted of the topical components of the SDD-regimen
and SOD-regimen, hereafter referred to as study medica-
tion, and of all systemic antibiotics used in ICU during
all periods, including the 4 days cefotaxime during SDD
as part of the SDD-protocol. The price of study medica-
tion was €0.87 and €10.48/day, for SOD and SDD,
respectively. Costs of systemic antibiotics were based
upon prices per Deﬁned Daily Dose (DDD) provided by
the Dutch information project on medication and
medical devices (Genees- en hulpmiddelen Informatie
Project (GIP)-database18). For microbiology costs blood
cultures, broncheoalveolar lavages, sputum, throat and
rectal cultures were considered. Rectal cultures were
only obtained during SDD as part of SDD-surveillance.
Cultures obtained from the other sites were either
obtained as part of the surveillance (throat and sputum
cultures during SDD/SOD) or as part of daily clinical
practice. Microbiological costs were obtained as the
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internal tariffs applied within the University Medical
Center, Utrecht. These costs included costs for the
microbiological culture, order tariff and extra costs for
species determination and susceptibility resistance
testing in case of relevant bacterial growth, irrespective
of the species. The year 2009 was taken as the reference
year for all costs. Costs that were not available for 2009
were corrected for inﬂation (with respect to 2009) based
on the price index.11 An overview of all unit costs used
in the analysis is provided in table 1. LYG were dis-
counted at 1.5% a year, following Dutch guidelines for
health economic evaluation.19 Discounting of costs was
not necessary, as all costs occurred within the ﬁrst year
after inclusion.20
Analysis
LYG were determined by calculating Life Years Lost
(LYL) of the patients who deceased in the hospital,
using life tables for the Dutch population combined
with age and sex,21 with LYG deﬁned as the difference
in LYL between regimens. The ICER was deﬁned as the
incremental difference between the mean cost of treat-
ment regimens, divided by the incremental difference in
mean effect between treatment regimens. To estimate
conﬁdence limits for the ICER, bootstrapping (25 000
repeats) was performed, as this does not depend on
parametric assumptions about the distribution of the
data.22 23 Results of the bootstrap procedure were
plotted in a cost-effectiveness plane that graphically
represents the cost-difference and effect difference
between either SDD or SOD and SC, and for SDD
versus SOD, for each of the bootstrap replications.
Cost-effectiveness acceptability curves (CEAC) were
plotted to express the probability that treatment regi-
mens were cost-effective as compared with SC, for a
range of willingness to pay levels for one LYG (λ).24 The
curves display the proportion of bootstrapped
ICER-pairs that are cost-effective, meaning that they
either fall within the south-east quadrant of the cost-
effectiveness plane or remain below the λ threshold in
the north-east and south-west quadrants of the plane. In
addition, sensitivity analyses were performed: the dis-
counted results (at 1.5% a year) were compared
with results without discounting and to a discount
rate of 3% a year; costs for ICU-days with mechanical
ventilation were analysed for 0% and 30% extra per
ICU-day as compared with 15% additional costs in base
case analysis; daily costs of study medication were ana-
lysed with maximum values based upon free market
prices in 2012 (€40 for SOD and €400 for SDD).
Mann-Whitney U test was used to calculate p values. p
Value <0.05 was considered to denote statistical signiﬁ-
cance and all reported p values are two-sided. All ana-
lyses were performed using Statistical Package for Social
Sciences V.20 (SPSS, Chicago, Illinois, USA) V.17.0 and
R V.2.14.2.
RESULTS
In this cluster-randomised trial 5939 patients were
included; 1990 patients in the SC group, 1904 received
SOD and 2045 received SDD. For this post hoc analysis,
19 patients were excluded (3 patients during SC, 3
during SOD and 13 during SDD). Twelve patients
declined permission to use clinical data. Seven add-
itional patients were excluded because data on hospital
discharge and/or hospital mortality was missing, as
reported previously.3
Baseline characteristics differed among the three
groups (table 2). Patients receiving SDD were on
average 62.4 (±15.8) years old, compared with 61.4
(±16.3) and 61.4 (±16.2) years for patients receiving
Table 1 Costs used per unit
Category Prices per unit
Length of stay
Day in ICU €218311
Day in hospital ward €50511
Mechanical ventilation, additional costs €327.4515–17
Topical antibiotics
Cost of SOD per day €0.873 42
Cost of SDD per day €10.483 42
Microbiology
Blood culture €11.89 per culture+€12.90 order rate*
Throat culture €7.78 per culture+€12.90 order rate*
Sputum culture €7.78 per culture+€12.90 order rate*
Bronchoalveolar lavage €7.78 per sample+€12.90 order rate*
Rectum culture €7.78 per sample+€12.90 order rate*
Species determination Extra €13.00 per isolate+€18.52*
Resistance profile determination 8.96 per isolate
Antibiotics According to GIP database18
*UMCU costs.
SC, standard care; SDD selective decontamination of the Digestive tract; SOD, selective oropharyngeal decontamination.
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SOD and SC, respectively. Patients receiving SC had a
lower mean APACHE II score (18.6) than those receiv-
ing SOD (19.6) and SDD (19.9), and were less likely to
be on mechanical ventilation (88.1% for SC vs 94.2%
and 92.9% for SOD and SDD, respectively).
Mean LOS in ICU and in hospital and mean duration
of mechanical ventilation did not differ signiﬁcantly
between SC, SOD and SDD. These data differ somewhat
from original LOS data reported previously,3 which
included only data of patients who were alive on day 28.
In all, 7609 daily doses of study medication were used
in the SOD group and 8068 during SDD, with average
numbers of 4 doses/day for SOD patients and 3.95 for
SDD patients. The average number of DDD of systemic
antibiotics during ICU-stay was the lowest during SDD
with absolute numbers of 33 688 DDDs during SC,
30 299 during SOD and 29 663 during SDD.
Cost analysis
Average total costs per patient were €41 941 for SC (95%
CI €40 184 to €43 698), €40 433 for SOD (95% CI €38 838
to €42 029) and €41 183 for SDD (95% CI €39 408 to
€42 958) (table 3). LOS accounted for approximately 98%
of total costs, and these costs were the highest for patients
during SC. Mean costs per patient for study medication
were €3.48 and €41.35 during SOD and SDD, respectively.
Mean costs of systemic antibiotics per patient were €358.29
(95% CI €321.34 to €395.24) during SC, €317.65 (95% CI
€280.89 to €354.42) during SOD and €439.14 (95%
CI €406.69 to €471.59) during SDD (p<0.01 for SDD vs SC
and SOD). Mean costs for microbiology cultures were the
highest for SDD (€ 371.72), as compared with SOD
(€287.27) and SC (€220.05; p<0.01 for SDD vs SC and
SOD).
Hospital mortality was 31.8%, 30.7% and 32.3%
during SC, SOD and SDD, respectively. The difference
in hospital mortality for SDD, as compared with
reported mortality previously3 (32.3% vs 32.6%), results
from inclusion of outcome data from the 12 patients
that declined permission to use clinical (not mortality)
data in the main analysis. Estimated LYL were, on
average, 6.07 years for SC patients, 5.62 years for SOD
patients and 5.97 years for SDD patients. Effects were
discounted with 1.5% a year resulting in LYG of
+0.25 years for SOD and +0.04 years for SDD as com-
pared with SC (table 4). SOD resulted in +0.21 LYG
when compared with SDD. In the cost-effectiveness
plane, point estimates of the differences in costs and
effects indicated that both SOD and SDD were beneﬁ-
cial and cheaper (ie, south-east quadrant) over SC. As
depicted in ﬁgure 1, SOD and SDD were dominant (ie,
southeast quadrant of plane) in 77.5% and 40.1% of the
bootstrap estimates, respectively. When comparing SOD
versus SDD, SOD dominates SDD in 60.2% of the boot-
strap replicates. If only cost aspects were taken into
account (ie, combining the south-east and south-west
quadrants), 89.3% and 72.4% of the bootstrap replicates
were cheaper than SC during SOD and SDD, respect-
ively. In addition, bootstrap results were graphically dis-
played in CEAC showing the probability that a treatment
is cost-effective in comparison with another treatment,
given a certain threshold value for the willingness to pay
Table 2 Baseline characteristics, clinical outcomes and resource use of patients
SC SOD SDD
N=1987 N=1901 N=2032
Baseline characteristics
Age (years) (mean (SD))**,*** 61.4±16.2 61.4±16.3 62.4±15.8
Male sex (no (%)) 1219 (61.3) 1211 (63.7) 1242 (63.7)
Apache II score (mean (SD))*,** 18.6±7.9 19.6±8.8 19.9±8.9
Mechanical ventilation (no (%))*,** 1751 (88.1) 1790 (94.2) 1888 (92.9)
Clinical outcome†
Length of MV (days) (median (IQR)) 6 (9) 7 (8) 6 (9)
Length of stay ICU (days) (median (IQR)) 8 (11) 9 (9) 9 (10)
Length of stay hospital (days) (median (IQR))‡ 15 (23) 15 (22) 15 (21)
Resource use
Study medication (DDD) (total (mean)) 0 7609 (4.0) 8068 (3.95)
Systemic antibiotics (DDD) (total (mean)) 33688 (5.9) 30299 (6.2) 29663 (5.2)
Microbiology (total (mean))
Rectal 0 0 7247 (3.8)
BAL 263 (1.3) 221 (1.3) 253 (1.3)
Sputum 5430 (3.7) 7467 (4.3) 8073 (4.4)
Throat 431 (2.7) 6277 (3.5) 7176 (3.8)
Blood 4113 (3.7) 4849 (4.1) 4461 (4.1)
p Value<0.05 for: *SC vs SOD; **SC vs SDD; ***SOD vs SDD.
†Values differ from previously reported values as not all patients could be included in the present analysis.
‡Duration in the hospital is the number of days in the hospital after ICU-discharge, for patients who were discharged from the ICU alive.
BAL, Brancheoalveolar Lavage; DDD, defined daily doses; ICU, Intensive Care Unit MV, mechanical ventilation; SC, standard care; SDD,
Selective Decontamination of the Digestive tract; SOD, Selective Oropharyngeal Decontamination.
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for one LYG. These probabilities varied for values
ranging from €0 to €20 000, between 89% and 93% for
SOD and between 63% and 72% for SDD (ﬁgure 1).
For SOD versus SDD, these probabilities varied from
73% to 87%.
In the cost-analysis, €69.59 per 1 DDD of cefotaxime
was used as reference price18 and average costs of sys-
temic antibiotics were the highest during SDD.3 The
price of 1 DDD cefotaxime should be €39.37 and €19.07
to balance costs for systemic antibiotics between SDD
and SC and SDD and SOD, respectively.
Sensitivity analyses on mechanical ventilation costs and
discount rates did not change the interpretation of
results (table 5, ﬁgure 1). Yet, daily costs of €10 and
€400 for study medication in SOD and SDD resulted in
an ICER of €21 590 per LYG for SDD versus SC whereas
SOD remained dominant over SC. For all situations,
SOD was more effective and cheaper than SDD (table 4
and 5). To stay below the Dutch threshold of €20 000
per LYG, the maximum daily price for the topical
SDD-components should be €375.
DISCUSSION
This post hoc analysis of a large cluster-randomised trial
performed in 13 Dutch ICUs including 5920 patients
revealed that both SOD and SDD are cost-saving and
more effective as compared with SC. These ﬁndings
were insensitive to changes in discount rates and extra
expenses for ventilation days. Furthermore, for SOD, but
not for SDD, these ﬁndings were insensitive to current
(higher) market-prices of the topical components. The
probabilities that SOD and SDD are cost-effective for a
willingness to pay threshold of €20 000 per LYG as com-
pared with SC, were 93% and 63%, respectively.
This is the ﬁrst head-to-head comparison of the costs
and beneﬁts of SDD and SOD and the ﬁrst comparison
of both interventions versus SC. Strengths of the present
study include the large study size and the completeness
of data collection.
Limitations of the study are the baseline differences
between the three study periods. Patients receiving SC
were younger, had lower APACHE II scores and were less
likely to receive mechanical ventilation and, therefore,
Table 3 Total costs (2009 €) per patient
SC SOD SDD
N=1990 N=1904 N=2045
Length of stay
ICU €29553.45 (€28152.40
to €30954.49)
€28684.46 (€27412.05
to €29956.87)
€29069.78 (€27636.40
to €30503.16)
Hospital €8621.85 (€8059.10 to €9184.61) €7830.55 (€7345.91 to €8315.20) €7963.94 (€7476.75 to €8451.13)
MV €3225.06 (€3045.61 to €3404.51) €3316.36 (€3151.14 to €3481.58) €3308.18 (€3116.09 to €3500.27)
Total €41400.36 (€39672.04
to €43128.68)
€39831.37 (€38261.92
to €41400.82)
€40341.90 (€38599.66
to €42084.14)
Study medication – €3.48 (€3.47 to €3.49) €41.35 (€41.07 to €41.62)*
Systemic
Antibiotics
€358.29 (€321.34 to €395.24) €317.65 (€280.89 to €354.42) €439.14 (€406.69 to €471.59)
Microbiology
Rectal swabs – – €102.75 (€97.64 to €107.86)
BAL €6.44 (€5.42 to €7.46) €4.70 (€3.92 to €5.49) €4.77 (€4.01 to €5.53)
Sputum €114.83 (€106.87 to €122.79) €135.85 (€127.99 to €143.71) €117.57 (€110.78 to €124.36)
Throat €8.12 (€6.39 to €9.84) €86.66 (€83.07 to €90.25) €89.65 (€85.68 to €93.63)
Blood €52.61 (€48.74 to €56.49) €53.72 (€49.64 to €57.79) €45.45 (€41.87 to €49.04)
Total €182.15 (€170.60 to €193.69) €280.93 (€267.00 to €294.87) €360.73 (€343.69 to €377.76)
Total €41940.79 (€40183.93
to €43697.66)
€40433.42 (€38837.50
to €42029.35)
€41183.12 (€39408.39
to €42957.85)
Mean (95% CI)*Excluding cefotaxim. Cefotaxim use is included in total systemic antibiotic use.
BAL, Brancheoalveolar Lavage; ICU, intensive care unit; MV, mechanical ventilation; SC, standard care; SOD, Selective Oropharyngeal
Decontamination; SDD, Selective Decontamination of the Digestive tract.
Table 4 Outcomes of cost-effectiveness comparisons across groups
LYG* Cost difference ICER
SOD vs SC (95% CI) +0.25 (−0.05 to 0.55) −€1507.37 (−€3186.45 to €171.72) SOD dominates SC
SDD vs SC (95% CI) +0.04 (−0.26 to 0.34) −€757.67 (−€2522.56 to €1007.21) SDD dominates SC
SOD vs SDD (95% CI) +0.21 (−0.09 to 0.51) −€749.69 (−€2439.35 to €939.97) SOD dominates SDD
*Effects are discounted at 1.5% a year.
ICER, incremental costs effectiveness ratio (costs/LYG); LYG, life years gained; SC, Standard Care; SDD, Selective Decontamination of the
Digestive tract; SOD, Selective Oropharyngeal Decontamination.
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seemed to have a better prognosis. In the original trial
random effects logistic regression modelling was applied
to adjust for these differences.3 Here we have used
crude data, without any adjustments for baseline differ-
ences. Our analysis points at superiority of SOD and
SDD when compared with SC, despite the somewhat
more favourable prognosis at the time of ICU-admission
of patients receiving SC. Our ﬁndings on the cost-
effectiveness of both interventions are, therefore, conser-
vative estimates. Furthermore, patients receiving SOD
were, on average, 1 year younger than those receiving
SDD, which may have affected the difference in LYL
between both interventions. Other limitations are the
restriction of cost data to the healthcare setting and the
absence of antibiotic and microbiology cost data after
ICU-discharge, which could not be obtained retrospect-
ively. Finally, this trial was performed in ICU-settings
with low endemicity of antibiotic resistance, which may
limit generalisability to other settings.
The main contributor to the total costs was LOS,
which was composed of stay in ICU and hospital after
ICU-discharge. The other costs, microbiology and anti-
biotics, were the highest for SDD, which had been
reported previously.25 Some relatively small single-centre
studies, also determined the effects of SDD on costs of
days in ICU or in the hospital. In a German study SOD
with cefotaxime prophylaxis resulted in lower average
costs for antibiotic therapy and for days on ventilation
than during SC.26 In a French study of trauma patients
both daily ICU-costs as well as mean antibiotic costs,
including SDD treatment, were lower during SDD com-
pared with SC.27 In a Spanish study mean costs of sys-
temic antibiotics were lower and less diagnostic
procedures for infections were performed during SDD,
compared with those during SC, which resulted in a
21% reduction of total costs per survivor in the
SDD-treated group.28 Yet, in none of these studies a
formal CEA was performed.
Figure 1 Scatterplot of
incremental cost-effectiveness
ratio pairs based on the results of
bootstrap resampling technique
(25 000 replicates) and
cost-effectiveness acceptibility
curves for (A and B) SOD vs SC,
(C and D) SDD vs SC and (E and
F) SOD vs SDD. SOD, selective
oropharyngeal decontamination ;
SDD selective decontamination of
the Digestive tract; SC, standard
care.
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Table 5 Sensitivity analysis
SC SOD SDD
ICER analyses
SC vs SOD
ICER analyses
SC vs SDD
ICER analyses
SDD vs SOD
Sensitivity analysis discounting effects (life years lost)
BC+1.5% 4.27 (3.96 to 4.57) 4.02 (3.72 to 4.32) 4.23 (3.94 to 4.53) SC=dominated by
SOD
SC=dominated by
SDD
SDD=dominated by
SOD
+0% 6.07 (5.58 to 6.55) 5.62 (5.15 to 6.08) 5.97 (5.50 to 6.44) SC=dominated by
SOD
SC=dominated by
SDD
SDD=dominated by
SOD
+3% 2.82 (2.63 to 3.01) 2.68 (2.49 to 2.87) 2.82 (2.63 to 3.00) SC=dominated by
SOD
SC=dominated by
SDD
SDD=dominated by
SOD
Sensitivity analysis
mechanical ventilation†
BC+15% €41940.79 (€40183.93
to €43697.66)
€40433.42 (€38837.50
to €42029.35)
€41183.12 (€39408.39
to €42957.85)
SC=dominated by
SOD
SC=dominated by
SDD
SDD=dominated by
SOD
+0% €38715.73 (€37112.32
to €40319.14)
€37117.07 (€35659.90
to €38574.24)
€37874.94 (€36270.73
to €39479.15)
SC=dominated by
SOD
SC=dominated by
SDD
SDD=dominated by
SOD
+30% €45165.85 (€43251.01
to €47080.69)
€43749.78 (€42010.47
to €45489.09)
€44491.30 (€42542.03
to €46440.57)
SC=dominated by
SOD
SC=dominated by
SDD
SDD=dominated by
SOD
Sensitivity analysis price
study regimen*,†
€41940.79 (€40183.93
to €43697.66)
€40493.15 (€38996.62
to €42189.67)
€42720.23 (€40943.82
to €44.496.65)
SC=dominated by
SOD
ICER 21590 SDD=dominated by
SOD
*Price SOD €40 and SDD €400 per day.
†Effects are discounted 1.5% a year.
BC, base case results; ICER, incremental costs effectiveness ratio (costs/LYG); SC, standard care; SDD, Selective Decontamination of the Digestive tract, SOD, Selective Oropharyngeal
Decontamination.
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VAP incidences were not determined in the Dutch
SDD-SOD trial3 because of the perceived difﬁculties in
uniformly diagnosing VAP in 13 ICUs. Yet, both SDD and
SOD have been associated with reduced incidences of VAP,
as compared with SC.5 29 In addition to SDD and SOD
there are other preventive measures that have been asso-
ciated with reductions in the incidence of VAP, such as the
use of silver-coated endotracheal tubes and continuous
subglottic suctioning (CSS). In a large multicentre rando-
mised controlled trial silver-coated endotracheal tubes
were associated with an RR reduction of the incidence of
VAP of 35.9%, without discernible beneﬁcial effects on
patient outcome.30 In a CEA of this trial the use of silver-
coated tubes, although 45-fold more expensive than
normal tubes ($90 vs $2 per tube), yielded savings of
$12 840 per episode of VAP prevented.31 CSS was, in a
recent meta-analysis of 13 randomised trials, associated
with a 45% reduction in the incidence of VAP (RR 0.55
(95% CI 0.46 to 0.66), but also without discernible beneﬁ-
cial effects on patient outcome (RR 1.01 (95% CI 0.85 to
1.20).32 The intervention appeared cost saving in two
studies, saving $4992 and €1176 per episode of VAP pre-
vented.33 34 However, these analyses were based on extra-
polated costs per episode of VAP, rather than on the true
costs generated during the trials. Other widely recom-
mended measures to prevent VAP, such as the semirecum-
bent patient position and different bundle approaches
have not been associated with documented improvements
in patient outcome and have not been evaluated with
formal cost-effectiveness analyses.
In conclusion, both SOD and SDD appeared more
beneﬁcial and cost saving as compared with SC and
even if the costs of both measures would increase
40-fold SOD will remain cost-saving and the ICER of
SDD will be around the Dutch threshold for cost-
effectiveness of €20 000 per LYG. The higher price for
medication follows from the higher costs for amphoteri-
cine B, which could be alleviated by replacing amphoter-
icine B by nystatin, which has also good antifungal
activity in topical application.35 With 1180 ICU-beds in a
country of 16.6 million inhabitants (year 2010), extrapo-
lation of our ﬁndings suggests that nationwide imple-
mentation of SOD or SDD in ICUs, as occurred after
the trial, has saved, per year, 18–36 million Euros.
The Dutch multicentre study on SDD and SOD pro-
vided evidence of better patient outcome,3 lower antibiotic
resistance prevalence in the ICUs,36 lower incidence of
ICU-acquired bacteraemia and ICU-acquired colonisation
of the respiratory tract with multiresistant bacteria,37 effect-
ive eradication of intestinal carriage with cephalosporin-
resistant Enterobacteriaceae,38 and low rates of resistance
development to colistin.39 Importantly, these beneﬁcial
effects were obtained in ICUs with low levels of antibiotic
resistance, reﬂected by incidence rates of bloodstream
infections caused by methicillin-resistant S aureus,
vancomycin-resistant enterococci and highly-resistant
Enterobacteriaceae of <0.1, <0.1 and 0.5 per 1000 patient
at risk, respectively.37 Whether these beneﬁts can be
realised in ICUs with different bacterial ecology remain to
be determined,40 but given the potential gains careful sci-
entiﬁc evaluation is warranted.41
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